Evidence map›Paper›PMID 38651743›Full record

ArticleNeurogastroenterology and motility2024

Predictors of irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease.

Mehwish Ahmed, Autumn Pu, Kara Jencks, Shrinivas Bishu, Peter Higgins, William D Chey, Krishna Rao, Allen Lee

Open access · hybridAbstract read
In one paragraph

Article in Neurogastroenterology and motility, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mehwish AhmedDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-9500-3401
Autumn PuDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Kara JencksDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-4248-5291
Shrinivas BishuDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Peter HigginsDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
William D CheyDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Krishna RaoDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Allen LeeDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
University of Michigan · USMayo Clinic · US

Funding

Data-Driven Interventions for Reducing C. difficile IncidenceR01HS027431 · AHRQ · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, KRISHNA, WIENS, JENNA · 2020 to 2024
$2.4M
CD4+ Tissue resident memory T-cells in Crohn's DiseaseK08DK123403 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BISHU, SHRINIVAS · 2020 to 2024
$848k
A Systems Biology Approach Using Fecal Microbiota and Metabolomics to Identify Novel Subtypes in Irritable Bowel Syndrome.K23DK124567 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEE, ALLEN A · 2021 to 2023
$729k
AHRQ HHS R01 HS027431NIDDK NIH HHS K08 DK123403NIDDK NIH HHS K23 DK124567NIH HHS DK123403NIH HHS DK124567NIH HHS HS027431
6 · The paper itself

Abstract

backgroundMany patients with quiescent inflammatory bowel disease (IBD) suffer from irritable bowel syndrome (IBS)-like symptoms. Although these symptoms cause significant reductions in quality of life, evidence-based treatments are lacking as risk factors and pathophysiology of these symptoms are not clearly defined. We aimed to identify risk factors for development of IBS-like symptoms in IBD patients with quiescent disease.

methodsWe performed a single-center retrospective cohort study of adults with IBD from 2015 to 2021. Quiescent IBD was defined by a fecal calprotectin level <250 μg/g of stool or endoscopic evidence of quiescent disease. Cox regression was performed to identify variables that were independently associated with the incident development of IBS-like symptoms in IBD patients. KEY

resultsA total of 368 IBD patients were included for analysis, including 278 patients with UC and 88 with Crohn's disease. 15.5% of quiescent IBD patients developed IBS symptoms, with an incidence rate of (95% CI 48.0-82.0) 63.3 per 1000 person-years. In the multivariate model, mood disorders (including anxiety and depression) and Crohn's disease were associated with increased risk for developing IBS symptoms. Male sex and higher iron levels conferred lower risk for developing IBS symptoms. Results from the multivariable model were similar in sensitivity analysis with quiescent IBD defined by fecal calprotectin level <150 mcg/g. CONCLUSIONS & INFERENCES: Mood disorder and Crohn's disease were positively associated with IBS-like symptoms in quiescent IBD, whereas male sex and iron levels were protective. Our results were robust to different fecal calprotectin levels, arguing against inflammation as a mechanism for IBS-like symptoms. This data suggests noninflammatory mechanisms may be important in the pathogenesis of IBS-like symptoms in quiescent IBD. Future work may address whether modifying these risk factors may alter disease course.

Indexed as

Inflammatory Bowel DiseasesIrritable Bowel SyndromeAdultCohort StudiesFecesFemaleHumansLeukocyte L1 Antigen ComplexMaleMiddle AgedRetrospective StudiesRisk FactorsLeukocyte L1 Antigen Complexbrain–gut axisCrohn's diseaseIBDIBS‐like symptomsulcerative colitis

Identifiers

PMID38651743
PMCPMC11806413
OpenAlexW4395049421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.